StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)

Investment analysts at StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZGet Rating) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, TheStreet downgraded shares of Enzo Biochem from a “c-” rating to a “d+” rating in a report on Tuesday, May 17th.

Enzo Biochem Stock Performance

Shares of ENZ stock opened at $2.36 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.92 and a current ratio of 2.52. The company has a market capitalization of $114.98 million, a P/E ratio of -18.15 and a beta of 0.85. The company’s 50 day moving average price is $2.46 and its two-hundred day moving average price is $2.59. Enzo Biochem has a 52 week low of $1.98 and a 52 week high of $4.15.

Enzo Biochem (NYSE:ENZGet Rating) last posted its quarterly earnings data on Thursday, June 9th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 5.88% and a negative return on equity of 1.98%. The business had revenue of $26.22 million during the quarter.

Insider Activity

In other Enzo Biochem news, Director Bradley Louis Radoff acquired 120,000 shares of the stock in a transaction dated Tuesday, July 5th. The shares were bought at an average cost of $2.20 per share, for a total transaction of $264,000.00. Following the completion of the acquisition, the director now directly owns 4,182,163 shares of the company’s stock, valued at $9,200,758.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 193,100 shares of company stock worth $426,524 over the last ninety days. Insiders own 17.40% of the company’s stock.

Hedge Funds Weigh In On Enzo Biochem

A number of institutional investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. acquired a new position in Enzo Biochem during the second quarter worth $38,000. Virtu Financial LLC acquired a new position in Enzo Biochem during the second quarter worth $62,000. Potomac Capital Management Inc. increased its holdings in Enzo Biochem by 12.6% during the second quarter. Potomac Capital Management Inc. now owns 559,500 shares of the medical research company’s stock worth $1,158,000 after buying an additional 62,695 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Enzo Biochem during the second quarter worth $41,000. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in Enzo Biochem by 0.5% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 951,235 shares of the medical research company’s stock worth $2,759,000 after buying an additional 4,950 shares during the last quarter. 43.29% of the stock is currently owned by institutional investors and hedge funds.

About Enzo Biochem

(Get Rating)

Enzo Biochem, Inc, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Further Reading

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.